People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of ...

Crinetics shares PATHFNDR trial data showing oral Palsonify maintained hormone and symptom control in acromegaly patients ...

People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of cancer, often at ages younger than typically seen in the general population, ...

In patients who transitioned from injected SRLs to once-daily oral PALSONIFY, mean insulin-like growth factor 1 (IGF-1) levels remained stable with IGF-1 (mean ± SE) of 0.93 ± 0.22 at OLE baseline and ...

The Palsonify-treated subjects maintained control, with stable growth hormone levels, symptom scores, and pituitary tumour ...